Microsulis Medical has licensed all rights of its Microwave Endometrial Ablation (MEA) technology in the gynecology and female urology fields of use to Hologic.

Microsulis CEO Stuart McIntyre said the system redefines the performance benchmark for tumour ablation devices in the interventional oncology market.

"Through the sale of our MEA platform to Hologic, we not only open our microwave technology to the most capable device developer in the woman’s health space, but we release the value of MEA to underpin the commercialization phase of our MTA device," McIntyre said.

"Hologic has the capability and market leadership needed to release the potential of our microwave technology to treat various female urological and gynecological conditions. There is no better company to nurture the technology in the woman’s health space.

"We look forward to working with Hologic over the next months and years in developing value from our technology portfolio. We are pleased that our customers will continue to be supported by such a capable company."